HR Execs on the Move

Talkiatry

www.talkiatry.com

 
Launched in April 2020, Talkiatry provides accessible in-network psychiatric care. The technology-driven service is committed to providing the highest level of mental health care on an outpatient basis. Based in New York City, Talkiatry offers seamless telehealth as well as in-person care in thoughtfully-designed, upscale offices—all at affordable, in-network prices. Talkiatry accepts a wide-range of insurance and employs psychiatrists and psychiatric nurse practitioners curated from among the city`s finest healthcare providers.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.talkiatry.com
  • 109, West 27th Street Suite 5S
    New York, NY USA 10001
  • Phone: 917.634.5311

Executives

Name Title Contact Details
Madeline Kuttner
VP of Growth Marketing Profile
Adrian Durelli
Vice President Patient Access and Customer Support Profile
Jill Cusick
Chief People Officer Profile

Similar Companies

Tahiti Trade Super Nutaceuticals

Tahiti Trade Super Nutaceuticals is a Riverside, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Micron Technologies

Micron Technologies is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nutra Manufacturing

Nutra Manufacturing, Inc is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Venture Healthcare Corporation

Venture Healthcare Corporation is a Leesburg, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virpax Pharmaceuticals

Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)